[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU3376193A - The use of xanthine derivatives for the treatment of muscle damage after interruption of the blood circulation - Google Patents

The use of xanthine derivatives for the treatment of muscle damage after interruption of the blood circulation

Info

Publication number
AU3376193A
AU3376193A AU33761/93A AU3376193A AU3376193A AU 3376193 A AU3376193 A AU 3376193A AU 33761/93 A AU33761/93 A AU 33761/93A AU 3376193 A AU3376193 A AU 3376193A AU 3376193 A AU3376193 A AU 3376193A
Authority
AU
Australia
Prior art keywords
atoms
interruption
radical
treatment
blood circulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU33761/93A
Other versions
AU658979B2 (en
Inventor
Michael Alfred Gregory
Maurice Mars
Ismahan Okyayuz-Baklouti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of AU3376193A publication Critical patent/AU3376193A/en
Application granted granted Critical
Publication of AU658979B2 publication Critical patent/AU658979B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Xanthine derivatives of the formula I <IMAGE> where at least one of the radicals R<1> and R<3> is a radical of the formula Ia <IMAGE> R<4> is a (C1-C3)-alkyl radical, n is an integer from 2 to 5 and, if only one of the radicals R<1> and R<3> is such a tertiary hydroxyalkyl group of the formula Ia, the other radical is a hydrogen atom or an aliphatic hydrocarbon radical R<5> which has up to 6 C atoms and whose carbon chain can be interrupted by up to 2 oxygen atoms or be substituted by an oxo group or up to two hydroxyl groups, these oxo and hydroxyl groups being separated from the ring nitrogen by at least 2 C atoms, and R<2> is an alkyl group with 1-4 C atoms, are suitable for the preparation of pharmaceutical compositions for the prophylaxis and treatment of muscle damage which may occur after interruption of the blood circulation.
AU33761/93A 1992-02-22 1993-02-19 The use of xanthine derivatives for the treatment of muscle damage after interruption of the blood circulation Ceased AU658979B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4205424 1992-02-22
DE4205424 1992-02-22

Publications (2)

Publication Number Publication Date
AU3376193A true AU3376193A (en) 1993-08-26
AU658979B2 AU658979B2 (en) 1995-05-04

Family

ID=6452327

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33761/93A Ceased AU658979B2 (en) 1992-02-22 1993-02-19 The use of xanthine derivatives for the treatment of muscle damage after interruption of the blood circulation

Country Status (13)

Country Link
EP (1) EP0557876B1 (en)
JP (1) JP3193800B2 (en)
KR (1) KR930017580A (en)
AT (1) ATE146078T1 (en)
AU (1) AU658979B2 (en)
CA (1) CA2089959A1 (en)
DE (1) DE59304710D1 (en)
DK (1) DK0557876T3 (en)
ES (1) ES2096115T3 (en)
GR (1) GR3022183T3 (en)
HU (1) HUT64472A (en)
TW (1) TW288977B (en)
ZA (1) ZA931184B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728686A (en) * 1995-11-02 1998-03-17 Hoechst Aktiengesellschaft Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as pharmaceuticals

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3792266B2 (en) * 1994-06-16 2006-07-05 森精機興産株式会社 Method and apparatus for correcting thermal displacement of machine tool
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
WO2007041506A1 (en) * 2005-10-03 2007-04-12 Melior Discovery, Inc. Purine formulations and methods for managing disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH608236A5 (en) * 1974-01-22 1978-12-29 Wuelfing J A Fa
DE3525801A1 (en) * 1985-07-19 1987-01-22 Hoechst Ag TERTIA HYDROXYALKYLXANTHINE, METHOD FOR THE PRODUCTION THEREOF, THE MEDICINAL PRODUCT CONTAINING IT AND THEIR USE
GB8621870D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Active compounds
ES2087205T3 (en) * 1990-11-07 1996-07-16 Hoechst Roussel Pharma USE OF XANTHINES FOR THE PREPARATION OF AN EFFECTIVE MEDICATION TO INHIBIT THE REPLICATION OF HUMAN RETROVIRUSES.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728686A (en) * 1995-11-02 1998-03-17 Hoechst Aktiengesellschaft Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as pharmaceuticals

Also Published As

Publication number Publication date
TW288977B (en) 1996-10-21
JPH069634A (en) 1994-01-18
ZA931184B (en) 1993-09-16
EP0557876A1 (en) 1993-09-01
CA2089959A1 (en) 1993-08-23
AU658979B2 (en) 1995-05-04
DK0557876T3 (en) 1997-05-26
JP3193800B2 (en) 2001-07-30
ES2096115T3 (en) 1997-03-01
KR930017580A (en) 1993-09-20
DE59304710D1 (en) 1997-01-23
HU9300476D0 (en) 1993-05-28
ATE146078T1 (en) 1996-12-15
HUT64472A (en) 1994-01-28
EP0557876B1 (en) 1996-12-11
GR3022183T3 (en) 1997-03-31

Similar Documents

Publication Publication Date Title
DK139287A (en) TERTIARY HYDROXYALKYLXANTHINES, THEIR PREPARATION AND USE AS MEDICINES
HU896769D0 (en) Fungicide compositions comprising azolylmethylcyclopentane-benzylidene-derivatives as active ingredient and process for preparation of the active ingredients
AU641772B2 (en) Novel anti-epileptics
AU4218093A (en) New peptides derived from trifluoromethyl ketones, process for their preparation and the pharmaceutical compositions which contain them
ATE73790T1 (en) AMINO 5,6,7,8TETRAHYDRONAPHTHO(2,3B&gt;FURANDERIVATE, PROCESS FOR THEIR MANUFACTURE AND MEDICATIONS CONTAINING THEM.
AU584274B2 (en) Process for the crosslinking of organopolysiloxanes
AU3376193A (en) The use of xanthine derivatives for the treatment of muscle damage after interruption of the blood circulation
IL91913A0 (en) Fluorosubstituted benzene derivatives,processes for the preparation thereof and diagnostic compositions containing the same
EP0528164A3 (en)
ZA906212B (en) Oxazolopyridine derivatives,process for preparing them and pharmaceutical compositions containing them
AU8699891A (en) Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses
DE3855902D1 (en) Manufacturing process for 2,5-diamino-6-nitro-pyridine derivatives and new 2,5-diamino-6-nitro-pyridine derivatives
CA2030732A1 (en) Thiophene derivatives; process for preparing the same and pharmaceutical compositions containing them
NZ216125A (en) Isoxazoles and pharmaceutical compositions
ES2096800T3 (en) BENZO (B) THIOFEN-3-IL-PIPERAZINES, A PROCEDURE FOR ITS PREPARATION AND USE AS MEDICINES.
AU4568093A (en) Novel acyclic amidine-group-containing diphosphonic acid derivatives, process for producing them and medicaments containing these compounds
SE7412163L (en)
FI954213A0 (en) Antitumor compositions and methods of treatment
IL93178A0 (en) Benzheterocyclyl sulphones
RU93004489A (en) MEDICINE FOR PREVENTION AND TREATMENT OF DAMAGE TO MUSCLE AFTER INTERRUPTION OF CIRCULATION AND METHOD OF TREATMENT

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired